Evotec
Dermot McGinnity has extensive work experience in the field of drug discovery and development. Dermot is currently the Executive Vice President and Head of Global Discovery DMPK at Evotec. Prior to this, they worked at AstraZeneca for several years, where they held various roles such as Executive Director and Senior Director, leading the DMPK teams in oncology R&D and drug safety and metabolism. Before joining AstraZeneca, they held senior positions at AstraZeneca R&D, including Senior Director of DMPK and Head of ADME function. Dermot also has experience from their time at the University of Michigan, where they worked as a Post-doctoral Research Associate.
Dermot McGinnity attended The University of Edinburgh from 1988 to 1995, where they obtained a BSc. and PhD in Biochemistry.
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.